rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    KOD
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Kodiak Sciences at UBS Global Biopharma Conference 2026: two-drug push
      Nov 17Investing.comKODUBS
      Kodiak Sciences at Jefferies Global Healthcare Conference: pipeline nears key readouts
      Nov 16Investing.comKODJEF
      Kodiak Sciences: Sticking With Hold As Optimistic Assumptions Are Already Priced In (KOD)
      Nov 13Seeking AlphaKOD
      Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial Results
      Nov 12Yahoo FinanceKOD
      Kodiak Sciences earnings in focus as BLA submission looms
      Nov 11Investing.comKOD
      Kodiak Sciences (KOD) Stock Looks At A Premium On Its Huge 3 Year Run
      Nov 10Yahoo FinanceKOD
      Kodiak Sciences stock hits 52-week high at 104.26 USD
      Nov 9Investing.comKOD
      Baker Bros. Advisors director buys $24.3M in Kodiak Sciences stock
      Nov 7Investing.comKOD
      Polen 5Perspectives Ultra-Small Growth Q3 2026 Portfolio Review
      Nov 4Seeking AlphaKOD
      Can Zenkuda's Multi-Indication Potential Drive KOD Stock Higher?

      Kodiak's Zenkuda shows promise across three retinal diseases, with positive phase III data and a planned 2026 regulatory filing.

      Oct 19Yahoo FinanceKOD
      H.C. Wainwright raises Kodiak Sciences stock price target on trial data
      Oct 12Investing.comKOD
      Kodiak Sciences Inc. (KOD) Presents at American Academy of Ophthalmology Conference 2026 - Slideshow (NASDAQ:KOD) 2026-10-10

      2026-10-10. The following slide deck was published by Kodiak Sciences Inc.

      Oct 10Seeking AlphaKOD
      Kodiak Sciences (KOD) Could Be 7% Overvalued Following Late Stage Data Update
      Oct 8Yahoo FinanceKOD
      Kodiak Sciences (KOD) Stock Trades At A Premium On DAYBREAK Trial News
      Oct 8Yahoo FinanceKOD
      Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026

      Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that clinical data across all three of its late-stage assets—Zenkuda (tarcocimab tedromer), tabirafusp-ted (KSI-501) and KSI-101— will be presented at the American Academy of Ophthalmology Annual Meeting (AAO 2026).

      Oct 7Yahoo FinanceKOD
      Analysts Are Bullish on Top Healthcare Stocks: Liquidia Technologies (LQDA), Kodiak Sciences (KOD)

      Detailed price information for Kodiak Sciences Inc (KOD-Q) from The Globe and Mail including charting and trades.

      Oct 6The Globe and MailKODLQDA
      Top 3 Health Care Stocks That May Collapse In Q4 - Iovance Biotherapeutics (NASDAQ:IOVA)

      Three healthcare stocks—Quantum-Si, Kodiak Sciences and Iovance—show overbought RSI readings above 80, warning momentum-focused investors.

      Oct 5BenzingaIOVAKODQSI
      Kodiak Sciences’ Two Wet AMD Treatments Match Aflibercept in Phase III Study

      Kodiak Sciences (NASDAQ:KOD) reported that its Phase III DAYBREAK study met primary endpoints for two investigational treatments in treatment-naïve patients with wet age-related macular degeneration, or wet AMD, with both therapies demonstrating statistical equivalence to aflibercept on visual-acuit

      Oct 2Yahoo FinanceKOD
      Kodiak Sciences More Than Doubles on Eye Disease Trial Results
      Oct 1BarchartKOD
      Why is Kodiak Sciences stock rallying today?
      Oct 1Investing.comKOD
      Exclusive BAC Article: Kodiak Sciences; Zenkuda Wet-AMD Win, Multi-Indication BLA Filings Q4 2026, KSI-501 Expansion Into DME, And Catalysts (NASDAQ:KOD)
      Sep 29Seeking AlphaKOD
      KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears

      Kodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.

      Sep 29Yahoo FinanceAMDKOD
      H.C. Wainwright raises Kodiak Sciences stock price target on trial data
      Sep 29Investing.comKOD
      Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and Kodiak Sciences (KOD)

      Detailed price information for Kodiak Sciences Inc (KOD-Q) from The Globe and Mail including charting and trades.

      Sep 29The Globe and MailKOD
      Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?
      Sep 29Yahoo FinanceKOD
      Why Kodiak Sciences Skyrocketed Today

      The biotech is developing innovative therapies for people with eye diseases.

      Sep 29Yahoo FinanceKOD
      KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’

      Martin Shkreli, who said he was short KOD before the readout, questioned Zenkuda’s edge over Eylea and dismissed the added IL-6 targeting in KSI-501.

      Sep 29Yahoo FinanceKODREGN
      MDB, KOD, NVTS, BA, NVDA: 5 Trending Stocks Today - NVIDIA (NASDAQ:NVDA)

      Major U.S. indices closed lower on Monday, with the Dow Jones Industrial Average falling 0.67% to 51,481.51.

      Sep 29BenzingaKODMDBNVTS
      Kodiak Sciences (KOD) Climbs Nearly 3x on Promising Wet AMD Trial

      Kodiak Sciences Inc. (NASDAQ:KOD) saw its share price nearly triple on Monday to a near five-year high, as investors loaded positions to cheer strong clinical trial results for its wet AMD treatment candidate. In intraday trading, the stock soared by as much as 196 percent before trimming gains to finish the session just up by […]

      Sep 28Yahoo FinanceAMDKOD
      Kodiak Stock Soars (Again) As Data Shows Long-Lasting Eye Meds Are 'Real Deal' (KOD)

      Kodiak Sciences Inc. stock jumps 140% on Phase 3 DAYBREAK wet AMD results. Click for this updated look at KOD and see if it belongs in your portfolio.

      Sep 28Seeking AlphaKOD
      Jefferies cuts Kodiak Sciences stock price target on valuation review
      Sep 28Investing.comKOD
      Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday - Kodiak Sciences

      U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial results; several small caps also rallied.

      Sep 28BenzingaAGENKODMBXAMC
      🔎 Under the Radar: Kodiak Stock Surges as Eye Drug Matches Regeneron’s
      Sep 28WSJKODREGN
      12 Health Care Stocks Moving In Monday's Intraday Session - Kodiak Sciences (NASDAQ:KOD), Accuray (NASDAQ

      Gainers Kodiak Sciences (NASDAQ:KOD) shares moved upwards by 172.3% to $88.08 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. Accuray (NASDAQ:ARAY) shares moved

      Sep 28BenzingaKOD
      Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial

      Kodiak Sciences Inc (NASDAQ:KOD) surged after Zenkuda and tabirafusp-ted met their primary endpoints in the phase III DAYBREAK trial for wet age-related macular degeneration. Shares gained over 162% by midday Monday following the announcement. Both experimental drugs demonstrated...

      Sep 28Yahoo FinanceKOD
      Stocks making the biggest moves midday: MongoDB, Boeing, Kodiak Sciences, Roblox, Nvidia & more

      Here are some of the companies making headlines in midday trading.

      Sep 28CNBCKODMDBRBLX
      Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results - Slideshow
      Sep 28Seeking AlphaKOD
      Kodiak skyrockets on positive study data for 2 eye drugs

      The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.

      Sep 28Yahoo FinanceKOD
      Kodiak Sciences options flow after positive Phase 3 DAYBREAK AMD trial data
      Sep 28Investing.comAMDKOD
      Kodiak’s stock rallies on Phase III wAMD success

      If approved, Zenkuda will compete with blockbuster wAMD sellers like Eylea and Vabysmo.

      Sep 28Yahoo FinanceKOD
      Kodiak Sciences skyrockets as Zenkuda, tabirafusp excel in late-stage wet AMD trial
      Sep 28Seeking AlphaAMDKOD
      Kodiak Sciences Soars 141% on “Truly Impressive” Pivotal Wet AMD Trial Win

      Key TakeawaysKodiak Sciences shares jumped about 141% after its drug Zenkuda met its primary endpoint in the pivotal Phase 3 DAYBREAK trial in wet AMD. Zenkuda’s edge is durability: it matched aflibercept on vision gains while 54% of its patients were on 6-month dosing under strict retreatment rules.

      Sep 28Yahoo FinanceAMDKOD
      Why Is Regeneron Pharmaceuticals Stock Falling Today? - Regeneron Pharmaceuticals (NASDAQ:REGN), Kodiak S

      Regeneron stock drops as Kodiak Sciences reports Phase 3 wAMD data showing Zenkuda rivals Eylea with extended six-month dosing schedules.

      Sep 28BenzingaKODREGN
      Nvidia, Meta, Kodiak Sciences, MongoDB, SpaceX, IonQ, and More Stocks That Explain Today’s Market

      Nvidia launches the largest-ever U.S. stock buyback.

      Sep 28Barron'sINTCKODMDBMUNVDASNDKSPCXBAIONQNIO
      Diabetic Macular Edema Market to Expand Rapidly with Advancing Pipeline and Increasing Treatment Adoption by 2034 – DelveInsight | Genentech, Novartis, Bayer, Regeneron Pharma, Santen, Kodiak Sciences
      Sep 28BarchartKOD
      This Biotech Company Added Nearly $3B To Its Market Cap – Here’s Why KOD Stock Is Ripping Today

      Kodiak Sciences shares saw their biggest ever single-day gains after the company posted positive Phase 3 data for 2 therapies targeting wet age-related macular degeneration.

      Sep 28Yahoo FinanceKOD
      Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine - Kodiak Sciences (NASDAQ:KOD)

      Kodiak Sciences announced positive data from its Phase 3 DAYBREAK study for its eye treatments Zenkuda and tabirafusp-ted.

      Sep 28BenzingaKODREGN
      Kodiak Sciences stock hits 52-week high at 61.28 USD
      Sep 28Investing.comKOD
      Why This Regeneron Eye Rival Just Catapulted More Than 120%

      Kodiak Sciences stock skyrocketed Monday on a double win for its potential rivals to Regeneron Pharmaceuticals' Eylea.

      Sep 28Investor's Business DailyKODREGN
      Kodiak Sciences Up 150% At Opening Bell After Drugs Pass Key Trial
      Sep 28ForbesKOD

      This is the newest page. Registered accounts read further back.